{"entity":{"id":"pim2","kind":"target","name":"PIM2","aka":["Pim-2 proto-oncogene, serine/threonine kinase","Serine/threonine-protein kinase pim-2"],"tldr":"PIM2 (Serine/threonine-protein kinase pim-2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","summary":"Proto-oncogene with serine/threonine kinase activity involved in cell survival and cell proliferation. Exerts its oncogenic activity through: the regulation of MYC transcriptional activity, the regulation of cell cycle progression, the regulation of cap-dependent protein translation and through survival signalling by phosphorylation of a pro-apoptotic protein, BAD. Phosphorylation of MYC leads to an increase of MYC protein stability and thereby an increase transcriptional activity.\n\nCIViC holds 1 clinical evidence item and 0 assertions across 1 variant.","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:8987","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8987"},{"label":"UniProt Q9P1W9","url":"https://www.uniprot.org/uniprotkb/Q9P1W9/entry"},{"label":"NCBI Gene 11040","url":"https://www.ncbi.nlm.nih.gov/gene/11040"},{"label":"Ensembl ENSG00000102096","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000102096"}],"tags":["cancer-genes-wave"],"related":["civic"],"cancers":["dlbcl"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC holds 1 clinical evidence items on its variants. Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"PIM2","role":["biomarker"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:8987","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8987","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt Q9P1W9","url":"https://www.uniprot.org/uniprotkb/Q9P1W9/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene PIM2","url":"https://civicdb.org/features/8813","note":"1 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma (GraphQL API, CC0)"}],"distribution":"one-type","specificityNote":"Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role biomarker; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA PIM2: RNA tissue enhanced (bone marrow 97 nTPM, intestine 82 nTPM, lymphoid tissue 153 nTPM); no normal tissue stained high. Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Lymphoma); Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)","specificitySources":[{"label":"Human Protein Atlas PIM2 tissue","url":"https://www.proteinatlas.org/ENSG00000102096-PIM2/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000102096 associations","url":"https://platform.opentargets.org/target/ENSG00000102096/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:8987","ensembl":"ENSG00000102096","uniprot":"Q9P1W9","entrez":"11040","firstDescribed":1998,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Baytel et al, Biochim. Biophys. Acta, 1998, \"The human Pim-2 proto-oncogene and its testicular expression\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/9804974/","biology":"Proto-oncogene with serine/threonine kinase activity involved in cell survival and cell proliferation. Exerts its oncogenic activity through: the regulation of MYC transcriptional activity, the regulation of cell cycle progression, the regulation of cap-dependent protein translation and through survival signalling by phosphorylation of a pro-apoptotic protein, BAD. Phosphorylation of MYC leads to an increase of MYC protein stability and thereby an increase transcriptional activity. The stabilisation of MYC exerted by PIM2 might explain partly the strong synergism between these 2 oncogenes in tumorigenesis. Regulates cap-dependent protein translation in a mammalian target of rapamycin complex 1 (mTORC1)-independent manner and in parallel to the PI3K-Akt pathway. Mediates survival signalling through phosphorylation of BAD, which induces release of the anti-apoptotic protein Bcl-X(L)/BCL2L1. Locus Xp11.23 (HGNC).","whereFound":["Diffuse large B-cell lymphoma: CIViC evidence names this disease"],"targetClass":"kinase","prevalence":[]},"route":"/targets/pim2/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"}],"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}]}}